HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Inter Parfums Expects ‘Another Spectacular Year’ As Prestige Fragrance Boom Continues

Executive Summary

The New York-based firm recorded 24% growth in fiscal 2023 first-quarter net sales to $311.7m. The performance reflects growth across all regions as consumers continue to splurge on more expensive fragrances in larger sizes, a trend that arose at the height of the global pandemic.

You may also be interested in...

IPAR Sales Grow 26% On 'Premiumization' Streak, As Symrise Earnings Stumble Over Production Issues: Briefs

New York-based Inter Parfums, Inc. says continued “premiumization’ trends in fragrance helped drive its sales up 26% in the second quarter, while German company Symrise AG’s two recent purchases in the fragrance space added 15m to sales in the first-half of the year. Separately, Revlon announces interim CEO as head Debra Perelman steps down.

A Need For Creed: Kering Beauté Acquires Platform For Luxury Fragrance Growth

Kering Beauté, a new division of luxury group Kering SA, acquires fellow Parisian Creed in an all-cash transaction expected to close in the second half of the year, giving it the largest global independent player in high-end fragrances with sales of around 250m.

Estee Lauder Companies’ Post-Pandemic Struggle Continues In Q3; Travel Retail Down 45%

Lauder lowers its fiscal 2023 full-year sales guidance a third time as travel retail recovery in Asia lags and global travel retail sales plunge 45% organically. On the bright side, the rest of the firm’s business grew 10%.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts